Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1995 Jun 3;345(8962):1392-7.
doi: 10.1016/s0140-6736(95)92596-1.

UK Medical Research Council Randomised, Multicentre Trial of Interferon-Alpha n1 for Chronic Myeloid Leukaemia: Improved Survival Irrespective of Cytogenetic Response. The UK Medical Research Council's Working Parties for Therapeutic Trials in Adult Leukaemia

Affiliations
Clinical Trial

UK Medical Research Council Randomised, Multicentre Trial of Interferon-Alpha n1 for Chronic Myeloid Leukaemia: Improved Survival Irrespective of Cytogenetic Response. The UK Medical Research Council's Working Parties for Therapeutic Trials in Adult Leukaemia

N C Allan et al. Lancet. .

Abstract

Interferon-alpha may be better than cytotoxic drugs in the long-term management of patients with chronic myeloid leukaemia (CML) in chronic phase. To test this possibility 587 patients with CML in chronic phase were randomly allocated to receive lymphoblastoid cell-line interferon-alpha n1 (IFN-alpha, n = 293) or chemotherapy with busulphan or hydroxyurea (no IFN-alpha, n = 294) as maintenance after initial induction treatment with cytotoxic drugs. There was a significant survival benefit for patients in the IFN-alpha arm when analysed on the basis of intention to treat (2p = 0.0009). The median survival for those allocated IFN-alpha was 61 months and no IFN-alpha was 41 months. Out of 269 patients with Philadelphia-positive CML in the IFN-alpha arm with at least 6 months follow-up, 211 were evaluable for haematological response: 145 (68%) achieved good responses (A+ or A type), 37 (18%) had partial responses (B type) and 29 (14%) had poor responses (C type). Patients with types A and B responses had a better survival than those in the no IFN-alpha arm; patients with type C responses had survival equivalent to the no IFN-alpha arm. Of these 269 patients, 26 of whom had not started IFN-alpha, 59 (22%) achieved a significant degree of cytogenetic response but 210 (78%) did not have a response. Cytogenetic responders survived significantly longer than non-responders and even non-responders survived longer than patients in the no IFN-alpha arm. Since cytogenetic non-responders had worse than average prognostic features, they may also benefit from IFN-alpha therapy. We conclude that treatment with IFN-alpha prolongs the survival of patients with CML; benefits of IFN-alpha are not confined to cytogenetic responders but may extend to most, if not all patients receiving IFN-alpha treatment; and cytogenetic response to IFN-alpha treatment identifies patients with a relatively good prognosis.

Similar articles

See all similar articles

Cited by 23 articles

See all "Cited by" articles

MeSH terms

Substances

Feedback